Skip to main content
ADTX
NASDAQ Life Sciences

Aditxt Seeks Shareholder Approval for Reverse Stock Split up to 1:250 to Maintain Nasdaq Listing

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$0.799
Mkt Cap
$411.385K
52W Low
$0.756
52W High
$5,214.678
52W Position info
5.6% above low
Off High info
100% below high
Rel. Volume info
3.4× avg
Market data snapshot near publication time

ADTX is trading near its 52-week low of $0.756 (5.6% above the low) on elevated volume (3.4× avg).

Summary

Aditxt, Inc. has filed its definitive proxy statement for its annual meeting, seeking shareholder approval for a reverse stock split with a wide ratio range (1:2 to 1:250) to maintain its Nasdaq listing, alongside other routine proposals.


Key Events · Corporate Governance and Compliance · ADTX

  • Shareholder Meeting Scheduled

    The Annual Meeting of Stockholders is scheduled for May 1, 2026, where shareholders will vote on key proposals.

  • Reverse Stock Split Proposal

    Shareholders will vote on granting the board discretionary authority to effect a reverse stock split at a ratio between 1-for-2 and 1-for-250 within one year, primarily to maintain Nasdaq listing compliance.

  • Nasdaq Compliance Efforts

    This proposal addresses the minimum bid price requirement, following the company's recent regaining of compliance with Nasdaq's minimum stockholders' equity rule.

  • Executive Compensation and Related Party Loans

    The filing details executive salaries, notes that management voluntarily forgave salaried payroll in 2024 and 2025, and discloses significant loans from the CEO to the company in 2024 and 2025, which were subsequently paid off.


Analysis · ADTX · Life Sciences

This definitive proxy statement confirms Aditxt's intent to pursue a highly aggressive reverse stock split, a critical measure to address Nasdaq's minimum bid price requirement. This follows the recent 10-K filing which raised substantial doubt about the company's ability to continue as a going concern and highlighted significant delisting risk. While the company recently regained compliance with Nasdaq's minimum stockholders' equity rule, the proposed reverse split underscores ongoing challenges in maintaining its listing. The wide discretionary range for the split ratio (up to 1:250) suggests the board is preparing for a significant adjustment to the share price, which could be highly dilutive for existing shareholders if followed by further capital raises through its expanded At-The-Market (ATM) program. The disclosure of management voluntarily foregoing salary and the CEO providing substantial loans in prior years further illustrates the company's precarious financial position and management's efforts to sustain operations. Investors should monitor the outcome of the shareholder vote and the subsequent board decision on the reverse split ratio, as it will significantly impact the stock's trading dynamics and the company's ability to raise further capital.

At the time of this filing, ADTX was trading at $0.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $411.4K. The 52-week trading range was $0.76 to $5,214.68. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ADTX - Latest Insights

ADTX
Jul 17, 2026, 12:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.0025
Real-time Price: $0.0029 info
Change: +$0.0004 (+16%) info
Market Cap: $2.894M info
ADTX
Jun 24, 2026, 11:36 AM EDT
Filing Type: 8-K
Importance Score:
10
Price at Filing: $0.050599
Real-time Price: $0.0029 info
Change: -$0.047699 (-94%) info
Market Cap: $2.894M info
ADTX
Jun 24, 2026, 3:13 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $0.0406
Real-time Price: $0.0029 info
Change: -$0.0377 (-93%) info
Market Cap: $2.894M info
ADTX
Jun 23, 2026, 4:23 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $0.0443
Real-time Price: $0.0029 info
Change: -$0.0414 (-93%) info
Market Cap: $2.894M info
ADTX
Jun 23, 2026, 4:22 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.0445
Real-time Price: $0.0029 info
Change: -$0.0416 (-93%) info
Market Cap: $2.894M info